Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGaming Realms Regulatory News (GMR)

Share Price Information for Gaming Realms (GMR)

Share Price is delayed by 15 minutes
Get Live Data
30.80    -0.60 (-1.91%)
Bid:
30.00
Ask:
30.80
Spread: 0.80 (2.667%)
Market Cap: £83.88m
GMR Live PriceLast checked at - London Stock Exchange

Intraday Gaming Realms Share Chart

Agreements signed with KFT

13 Apr 2011 07:39

RNS Number : 8173E
Pursuit Dynamics PLC
13 April 2011
 



13 April 2011

 

Pursuit Dynamics PLC ("PDX" or "the Company")

 

Development and distribution agreements signed with Kaercher Futuretech GmbH ("KFT")

PDX is pleased to announce that it has signed development and distribution agreements with KFT to structure the commercial cooperation between the companies that was first announced in April last year. PDX has formed a dedicated subsidiary, DDX Solutions AG, through which it will work with KFT to deliver a series of innovative products starting this calendar year.

 

KFT, a wholly owned subsidiary of Alfred Kaercher GmbH, the world's leading manufacturer of high-pressure cleaning and disinfectant equipment will, together with PDX, jointly develop, produce and market civilian and military decontamination and disinfection products for the global market. The cooperation combines KFT's experience as a world leader in decontamination solutions and its core competencies in manufacturing, distribution and after sales support, with PDX's best in class technology to form a new product range focused on quality, mobility and efficiency.

 

The relationship between KFT and PDX has been established by two multi product contracts - a development agreement and a distribution agreement - that create clear lines of responsibility and accountability. The structure affords PDX ownership of the products as well as control over design and development. KFT will manage manufacturing orders, inventory and spare parts. KFT will also be responsible for marketing and distribution and will also bear all marketing and distribution costs.

 

In addition, as part of the agreement, KFT will guarantee a minimum sales threshold to be agreed each year to maintain its right to distribute the jointly developed products.

 

Under the agreements, PDX will be entitled to receive a margin on all sales of equipment, parts and chemical products.

 

The first product to go to market will be the First Responder System, utilising PDX's atomisation technology. Prototype testing of both the backpack and trolley models is well under way with mass manufacture expected to begin in Q3 of this calendar year. Sales pipeline development will begin shortly thereafter with the first product shipments due in Q4 of this calendar year. The initial feedback from premarketing has been encouraging, with a number of major organisations expressing high levels of interest.

 

KFT and PDX are also developing a hospital mobile decontamination product, the development of which has been accelerated due to positive market feedback. PDX expects a further three product lines to be delivered later this year and through 2012. Further details will be provided in due course.

 

Roel Pieper, CEO of PDX, commented:

 

"With this agreement PDX is now extremely well placed to drive significant commercial returns from the multi-billion dollar global mobile decontamination market. The agreements with KFT give us a competitive product offering in the global chemical and biological decontamination markets, whilst NDX, PDX's joint venture with the UK's National Nuclear Laboratories, positions us in the nuclear decontamination market as well. I am extremely excited by this business and I am looking forward to a long and fruitful cooperation with KFT."

 

Hagen Gehringer, Managing Director of KFT, commented:

 

"PDX's unique technology enables us to bring to market state of the art products and create best in class applications. With their innovation and our experience and know-how we have formed a formidable partnership. We are excited by the significant opportunities that we are addressing." 

 

- Ends -

 

 

For Further Information, please contact:

 

PDX

Roel Pieper, CEO

Tel: +44 (0)1480 422050

Richard Webster, CFO

Financial Dynamics

Ben Foster

Marc Cohen

Tel: +44 (0) 20 7831 3113

 

Cenkos Securities

Ian Soanes

Max Hartley

Tel: +44 (0)20 7397 8924

Mirabaud Securities

Rory Scott

Tel: +44 (0) 20 7878 3360

 

Notes to Editors

 

About PDX

 

- PDX (AIM: PDX) owns and commercialises the PDX Atomiser and Reactor

technologies that enable significant reductions in energy usage, process acceleration and result enhancement for a wide range of industrial processes and applications.

 

- The PDX business model is currently organised into five Lines of Business

Biofuels; Brewing, Food and Beverages; Public Health and Decontamination

Industrial Licensing; Water.

 

- PDX is headquartered in Huntingdon (UK) with an office in London (UK),

Schaffhausen (Switzerland) and Connecticut (USA).

 

- Further information is available at the Company's website: www.pdx.biz 

 

- Publication quality photographs are available from FD.

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRGLGDSRXBBGBX
Date   Source Headline
30th Jul 202512:15 pmRNSTotal Voting Rights and Share Capital
30th Jul 202512:15 pmRNSBLOCK LISTING SIX MONTHLY RETURN
29th Jul 20257:00 amRNSPre-Close Trading Update
2nd Jul 20253:37 pmRNSTotal Voting Rights and Share Capital
25th Jun 202511:45 amRNSDirector/PDMR Shareholding & Total Voting Rights
23rd Jun 202512:47 pmRNSHolding(s) in Company
4th Jun 202512:40 pmRNSResult of AGM
2nd Jun 20252:01 pmRNSTotal Voting Rights and Share Capital
15th May 20253:00 pmRNSAdoption and grant of options
1st May 20257:00 amRNSTransaction in Own Shares
28th Apr 20257:00 amRNSTransaction in Own Shares
25th Apr 20257:00 amRNSTransaction in Own Shares
24th Apr 20257:00 amRNSTransaction in Own Shares
23rd Apr 20257:00 amRNSTransaction in Own Shares
22nd Apr 20257:00 amRNSTransaction in Own Shares
17th Apr 20257:00 amRNSTransaction in Own Shares
15th Apr 20257:00 amRNSTransaction in Own Shares
14th Apr 20257:00 amRNSTransaction in Own Shares
11th Apr 20257:00 amRNSTransaction in Own Shares
10th Apr 20257:00 amRNSTransaction in Own Shares
9th Apr 20257:00 amRNSTransaction in Own Shares
8th Apr 20257:00 amRNSTransaction in Own Shares
7th Apr 20257:00 amRNSTransaction in Own Shares
4th Apr 20257:00 amRNSTransaction in Own Shares
3rd Apr 20257:00 amRNSTransaction in Own Shares
2nd Apr 20257:00 amRNSTransaction in Own Shares
1st Apr 20257:00 amRNSTransaction in Own Shares
31st Mar 20257:02 amRNSShare Buyback Programme
31st Mar 20257:00 amRNSAnnual Results 2024
28th Feb 202512:05 pmRNSTotal Voting Rights and Share Capital
4th Feb 20257:00 amRNSFY24 Pre-Close Trading Update
29th Jan 20253:45 pmRNSBlock Listing Six Monthly Return
22nd Jan 20253:20 pmRNSHolding(s) in Company
11th Sep 20247:00 amRNSInterim Results
7th Aug 20243:00 pmRNSAdoption and grant of options
2nd Aug 20245:00 pmRNSShare Capital Reduction
30th Jul 20247:00 amRNSPre-Close Trading Update
29th Jul 20248:00 amRNSBlock Listing Six Monthly Return
27th Jun 20242:20 pmRNSTotal Voting Rights and Share Capital
14th Jun 20249:57 amRNSResult of AGM
2nd Apr 20247:01 amRNSInvestor Presentation
2nd Apr 20247:00 amRNSAnnual Results 2023
27th Mar 20244:05 pmRNSTotal Voting Rights and Share Capital
5th Feb 20247:00 amRNSPre-Close Trading Update
30th Jan 20244:00 pmRNSTotal Voting Rights and Share Capital
30th Jan 20244:00 pmRNSBlock Listing Six Monthly Return
30th Nov 20237:00 amRNSTotal Voting Rights and Share Capital
28th Sep 20237:00 amRNSInvestor Presentation
12th Sep 20237:00 amRNSInterim Results
14th Aug 20237:00 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.